CLiC Poll #2: Survey re. MURANO 48-month data presented at iwCLL conference 2019

On behalf of the CLiC Leaders, we invite you to participate in the following poll. Click here to answer.

Note that the following questions refer to the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Carolyn Owen’s podcast available here.

1. Based on the MURANO 48-month data presented at iwCLL conference 2019, reviewed in Dr. Owen’s podcast, should MRD testing (positive MRD) be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?

  • Yes
  • No
  • Maybe

2. Based on the MURANO 48-month data, should high risk cytogenetics be used to tailor treatment with VR given 27% of patients who discontinued treatment have now progressed?

  • Yes
  • No
  • Maybe
3. Based on the MURANO 48-month data, should everyone stop treatment at 24 months?
  • Yes
  • No
  • Maybe

Click here to answer